Cabaletta Bio, Inc.
As of Oct 22, 2026, Cabaletta Bio is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $1.52, 63.4% below its 52-week high and below its 200-day average, which is falling.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CABA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CABA among Biotechnology334th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …334 | CABA | Stage 4 · wk 5 | 26 | −31.5% |
Cabaletta Bio: quick answers
What stage is Cabaletta Bio in?
As of Oct 22, 2026, Cabaletta Bio (CABA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean
Is Cabaletta Bio in an uptrend?
No. Cabaletta Bio is in a Stage 4 downtrend. It trades 47.2% below its 200-day average, which is falling.
How far is Cabaletta Bio from its 52-week high?
Cabaletta Bio closed at $1.52 on Oct 22, 2026, 63.4% below its 52-week high of $4.15. Its 52-week low is $1.41.
How has Cabaletta Bio performed over the past year?
As of Oct 22, 2026, Cabaletta Bio is down 44.5% over the past year and down 31.2% so far in 2026.
Which sector and industry is Cabaletta Bio in?
Cabaletta Bio is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.